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Abstract 
Compelling evidence has shown a pivotal role of 
dopaminergic function in drug addiction. Recently, the 
Habenula (Hb) has attracted a great deal of attention as 
another target for nicotine in the brain because of its role 
in regulating dopamine (DA), gamma-aminobutyric acid 
(GABA) and serotonin (5-HT) systems. Nicotine acts 
binding to acetylcholine receptors that are widely 
distributed in the brain. Interestingly, the receptor subtypes 
that mediate nicotine withdrawal responses are highly 
expressed in the Hb. Moreover, the block of habenular 
nicotinic receptors in animals chronically treated with 
nicotine enhances withdrawal responses once nicotine is 
discontinued. Furthermore, it has been shown how a high 
dose of nicotine can cause massive degeneration almost 
exclusively in the medial habenula (MHb) and its output 
tract, the fasciculus retroflexus. Thus, symptoms 
associated with nicotine withdrawal may be caused by 
dysfunctions of the Hb output. Therefore, Hb might be of 
fundamental importance in the expression of nicotine 
reinforcing properties and withdrawal. Here, we will focus 
on the role of the lateral habenula (LHb) on nicotine 
modulation of DA function and we will evaluate LHb 
interaction with the rostromedial tegmental nucleus 
(RMTg), a GABAergic area, and the serotonergic raphé 
nuclei. Furthermore, as LHb has high density expression of 
5-HT2C receptors, these subtypes might be important in the 
control of its neuronal activity and output to the midbrain 
monoaminergic and GABAergic systems. 
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Introduction 
Tobacco addiction represents a serious social problem 
with major impacts on public health, representing the 
second-leading cause of death in the world. The number of 
yearly deaths in Malta attributable to smoking has risen by 
28% from 289 in 1987 to 372 in 2008 as estimated by the 
Department of Health Information and Research (DHIR, 
2008), i.e. approximately one death a day. The economic 
burden that tobacco use incurs to public health care 
services is high on Malta’s financial agenda. Thus, there is 
an urgent need for a better understanding of the 
neurobiological bases of nicotine action, dependence and 
withdrawal, and new and more efficacious therapy for 
smoking cessation. 
 
Nicotine acts by binding to nicotinic acetylcholine 
receptors (nAChRs) that are widely distributed throughout 
the central nervous system, as well as in the periphery. 
These receptors are pentameric structures assembled from 
5 sub-units arranged around a central water-filled pore to 
form a receptor belonging to the superfamily of ligand-
gated ion channels.1-4 A wide variety of subtypes of 
nAChRs arise from the combination of the different 
subunits that compose the channel-receptor complex. In 
the mammalian central nervous system, nAChRs are 
composed by the combination of seven different 
α (α2−7, α9) and three β (β2-4) subunits to form either 
homomeric (α7) or heteromeric (α4β2) receptors.5,6 This 
subunit composition represents a major factor in 
determining pharmacological and functional properties of 
these receptors. For instance, the α4 and β2 containing 
nAChR, the most represented in the mammalian brain, is 
characterized by the highest binding affinity to nicotine as 
well as by high sensitivity to upregulation following 
nicotine administration.7,8 The inclusion of the α5 subunit 
in these receptors is able to modify their properties, such 
as enhancement of receptor expression, reduction of 
ligand-mediated upregulation and facilitation of receptor 
closure.9,10 Moreover, some additional subunits can 
participate in the formation of these high affinity nAChRs 
specifically in some brain areas. Thus, α6 and β3 subunits 
have been shown to be included in α4β2 nAChRs to 
generate high-affinity receptors specifically in the basal 
ganglia, including the ventral tegmental area (VTA) and 
substantia nigra (SN), representing a relevant evidence for 
Parkinson’s disease.11,12 Finally, nAChRs assembled with 
the same subunits but in different stoichiometries show 
differences in their functions and pharmacological 
properties. For example, it has been shown that, while all 
α4β2–containing nAChRs of different stoichiometry bind 
nicotine with the same high affinity, only the (α4)2(β2)3 
nAChR shows the highest sensitivity to upregulation by 
nicotine13. 
The neural substrate for nicotine dependence and 
addiction is represented by the mesocorticolimbic 
neural system of the mammals’ midbrain. One of the 
key components is the dopaminergic (DAergic) system 
that originates in the VTA and projects to the nucleus 
accumbens (NAcc) and medial prefrontal cortex 
(mPFC). This system has long since been implicated in 
playing a pivotal role in mediating and processing 
environmental rewards, as indicated by the earliest 
studies involving intracranial electrical self-
stimulation.14 The DAergic system has been involved 
in the reinforcement of reward-directed behaviours 
and likewise in the acquisition of behaviours that are 
inappropriately reinforced by addictive drugs like 
nicotine.15,16 Thus, blocking of DA terminal release in 
the NAcc, by either localized lesion or DA antagonists 
administration, decreases nicotine self-administration 
in rats.17 In the VTA, nAChRs are localized both post-
synaptically on DA neurons and pre-synaptically on 
glutamatergic and GABAergic terminals innervating 
DAergic neurons.18 Nicotine, inhaled with tobacco 
smoke, reaches a concentration that is enough to 
increase firing rate and burst firing of DA neurons by 
binding to nAChRs expressed on these neurons.19 
These receptors are mainly α4β2 which, as described 
previously, have a high binding affinity and undergo 
fast desensitization, usually within few minutes 
following nicotine administration. Simultaneously, α7 
containing nAChRs, located pre-synaptically on 
glutamatergic terminals, are activated by nicotine 
boosting the glutamatergic drive of VTA DA neurons. 
These receptors, despite the α4β2, are not desensitized 
by nicotine because of their low binding affinity for 
this agonist, thus resulting in a long lasting effect 
together with long-term potentiation (LTP) induction 
on glutamatergic afferents.20,21 Finally, nicotine 
induces desensitization of β2-containing nAChRs 
receptors expressed on VTA GABA interneurons 
leading to a reduction of their inhibitory influence on 
DA neurons.19,22-24 
 
It is now well know how VTA DAergic neurons 
can respond to events of opposite hedonic valence 
with a change of their neuronal activity.25,26 In 
particular, these neurons are known to inhibit their 
firing activity in response to aversive stimuli or events 
with negative motivational values, such as reward 
omissions. Since the neural activity of DA neurons 
depends on the balance between excitatory and 
inhibitory inputs of its afferents, it is important to 
know the neural pathway encoding of these 
motivational values in order to better understand how 
hedonic information is processed and thus to have a 
more complete understanding of how addictive drugs 
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like nicotine can exert their effects. Recently, a great deal 
of attention has been attracted by the lateral habenula 
(LHb). The habenular complex is an epithalamic structure 
involved in anxiety, stress, depression, schizophrenia, 
divided into a medial (MHb) and lateral (LHb) portion. 
The former receives afferent innervations from limbic 
structures and projects to the interpeduncular nucleus, 
while the latter receives its input mainly from the basal 
ganglia and sends efferent projections to the DAergic and 
serotonin (5-HT)-containing neurons of the VTA and the 
dorsal raphé (DR), respectively.27-29 Both morphological 
and functional evidence clearly demonstrated the existence 
of an inhibitory control exerted by the LHb over VTA DA 
neuronal activity.30,31 Most importantly, recently published 
data obtained on monkeys showed how LHb neurons 
respond to reward related signals in an opposite manner to 
DA neurons of the VTA. In particular, LHb neurons have 
been shown to encode for aversive stimuli with a phasic 
increase of their firing rate that, in turn, corresponds to a 
DA neurons inhibition in the VTA.32,33 Since LHb 
efferents to the VTA are mainly glutamatergic, this implies 
that such inhibition is not direct but rather involves a 
multi-synaptic pathway. Thus, recent evidence identified 
the presence of an area located just posterior to the VTA, 
indicated as the rostro-medial tegmental nucleus (RMTg) 
or tail of the VTA, which receives a massive glutamatergic 
afferent input from the LHb and sends GABAergic 
projections to the VTA.34-39 Morphological data also 
showed how this area receives convergent afferent 
innervations from various areas located within both the 
forebrain and brainstem, thus suggesting a role in 
integrating these influences with the dominant LHb input 
and in modulating both ascending and descending 
pathways output.39 In fact, this area is activated by 
aversive and inhibited by rewarding stimuli, similarly to 
the LHb, suggesting its involvement in integrating reward-
related information and passing it onto VTA DA neurons. 
Moreover, it has been shown that RMTg neurons can be 
modulated by systemically administered drugs of abuse, 
like cocaine or methamphetamine, and they are also 
strongly activated by nicotine.40 
 
Nicotine modulation of later habenula neuronal activity 
Nicotine administration produces positive effects, as 
demonstrated by nicotine intravenous self-administration 
behaviours observed in different mammals species like rats, 
mice and non human primates.17,41,42 Chronic nicotine 
exposure leads to neuroadaptations that include 
tolerance and up-regulation, thus leading to a new 
homeostatic condition which requires a constant 
concentration of nicotine to be maintained. When 
nicotine intake is discontinued, a withdrawal syndrome 
emerges which is characterized by negative somatic 
and affective symptoms like irritability and anxiety. 
The avoidance of these negative symptoms associated 
with drug withdrawal is responsible for the drug 
seeking behaviours and motivates nicotine use, 
representing the main cause of relapse following 
discontinuation of the tobacco smoking habit. 
 
Since it has been shown that the LHb plays an 
important role in processing aversive, negative sensory 
inputs, it is likely that this structure plays an important 
role in mediating withdrawal symptoms. Furthermore, 
it has been shown that chronic exposure to nicotine 
induces degeneration of fasciculus retroflexus’ axons, 
the main output of the habenular complex,43 thus 
further suggesting an involvement of this structure in 
nicotine addiction. So far, there are no functional data 
illustrating how LHb neuronal activity is affected by 
nicotine administration. Some preliminary data we 
have obtained in our laboratory show that nicotine is 
able to increase the neuronal activity of LHb neurons 
when injected systemically (Figure 1a). The intra-
venous administration of single bolus of different 
doses of nicotine elicited an increase of basal firing 
rates characterized by a fast onset and followed, at the 
highest doses, by a complete silencing of the neurons, 
probably because of the intervention of depolarization 
block mechanisms. When nicotine was injected as 
cumulative doses, recorded neuronal activities 
displayed an inverted-U-shape type of response 
(Figure 1b), with an initial increase at the lowest doses 
followed by a reduction of their firing rates that, in 
some cases, reached a complete silencing. Finally, 
nicotine administration directly in the LHb was able 
again to increase neuronal firing rates of a sub-
population of the recorded neurons (Figure 1c), thus 
demonstrating the presence of nAChRs in the LHb and 
showing that the neuronal activation, induced by 
systemic administration of nicotine, is partially 
mediated by the activation of habenular nAChRs.
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Figure 1 
Nicotine increases LHb neuronal activity following systemic or local administration in the LHb. Rate meters show 
nicotine induced changes in basal firing rate of LHb neurons recorded in vivo on anaesthetized rats using the 
single unit extracellular recording technique. Each column in a trace represents the number of action potentials 
(spike) fired in a 10 seconds time bin. A) Effect of intravenous injection of single bolus of nicotine. Arrows 
indicate the time of injections of either nicotine or saline. Nicotine injection elicited a fast on-set increase of firing 
rate, followed by a slow decrease. B) Intra-venous injection of cumulative doses of nicotine elicited a inverted-U-
shaped response in firing rate. C) Microionthophoretic  administration of nicotine in the LHb increased basal 
firing rates in a current (dose) dependent manner; bars indicate time and duration of nicotine ejection in the 
extracellular space of the recorded neuron. 
 
 
Lateral habenula, rostro tegmental area and raphé 
nuclei interactions 
As stated above, a part from the LHb innervation, the 
RMTg receives afferents from both the DR and, to a lesser 
extent, the median (MR) raph nuclei.39 Moreover, LHb and 
DR reciprocal innervations have been proved on both a 
morphological and functional basis.44,45 Thus, the 
modulatory control of the serotononergic system over the 
neural circuit involving the LHb, RMTg and midbrain DA 
neurons might represent an important substrate for nicotine 
addiction. 
 
The 5-HT/DA interaction has been demonstrated to 
largely depend upon the different 5-HT receptor sub-types 
expressed by the targeted neurons. A particular emphasis 
has been placed on the role of the 5-HT receptor subtype 
2C (5-HT2C) in modulating the activity of the midbrain 
DAergic system46-49, highly expressed in VTA/SNc and in 
other areas receiving DA-ergic innervation. Several studies 
have demonstrated the efficacy of 5-HT2C selective 
activation in blocking the stimulatory action of nicotine on 
midbrain dopamine function, as well as its behavioural 
effects,50-52 thus suggesting a role for this receptor as a 
potential target in treating nicotine dependence.53 Since the 
presence of 5-HT2C mRNA has been demonstrated in the 
LHb54,55 and our preliminary data show 5-HT2C 
immunoreactivity at the level of the RMTg, these two 
areas may play an important role in 5-HT2C block of 
the nicotine-induced DAergic hyperactivation. 
Therefore, the LHb and RMTg might play a central 
role in the brain reward circuitry. 
 
Conclusions 
Although mounting research findings on nicotine 
have revealed many of its effects, we are far from a 
full understanding of the complete scenario. The 
habenula complex has been shown to affect DA, 5-HT 
and GABAergic systems activity, suggesting it might 
play a role in nicotine action in the CNS. However, the 
extent to which the habenula may contribute to the 
neurobiological action of nicotine still needs to be 
fully addressed. The evidence reviewed in this paper 
shows a potential pivotal role for 5-HT in the 
modulation of the neural circuitry involving the LHb, 
RMTg and VTA DA system. Thus, 5-HT system may 
represent a good candidate for new smoking cessation 
therapies. In particular, the 5-HT2C receptors have 
already been proved to counteract the effects elicited 
by nicotine on the DA system and, because of its 
distribution within the LHb-RMTg-VTA circuitry, it 
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may represent an important pharmacological target in 
treating nicotine addiction and alleviating withdrawal 
symptoms associated with smoking cessation. 
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